Curaleaf Responds To FDA Warning Letter


Earlier this week, the Meals and Drug Administration (FDA) issued a warning letter to Massachusetts-based, multi-state cannabis operator Curaleaf Holdings, Inc. to advise the corporate that a few of the advertising for cannabidiol (CBD) merchandise on its web site and social media pages was in violation of the Meals, Drug, and Beauty (FD&C) Act and FDA laws

Curaleaf responded to the FDA on Thursday, informing the company that the problems introduced within the letter had been addressed.

Upon receipt of the FDA warning letter, Curaleaf Hemp carried out a full evaluate of its web site and social media platforms to take away non-compliant statements and claims concerning the firm’s merchandise.

The corporate additionally eliminated the Curaleaf Hemp weblog and took down all third social gathering hyperlinks in it.

In response to Curaleaf, a few of the merchandise that had been listed within the FDA warning letter had been beforehand discontinued.

“We care deeply about our clients and making a distinction in our business,” mentioned Curaleaf CEO Joseph Lusardi in a press release. “Curaleaf is dedicated to being an moral and accountable firm and dealing with the FDA to be a frontrunner in our business, setting the requirements and tips to finest service our clients and the communities we serve.”

Lusardi says that the business wants, desires, and appreciates the work that the FDA is doing to make sure regulation and compliance within the CBD market.



Latest posts